SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1228 participants.
Also called NCT06590012
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,228 participants
- Registry
-
NCT06590012
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06590012. Randomized; triple masking; primary purpose treatment. Start 2024-08-29 (actual); primary completion 2027-07-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY
- Acronym
- SIAT
- Condition
- Atherosclerosis
- Condition
- Atheroscleroses, Coronary
- Condition
- Carotid Atherosclerosis
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Tertinat
- Lead sponsor
- Institute for Atherosclerosis Research, Russia
Record details
- Record id
cardio:ct-nct06590012- Content hash
ad1953450161b18db21d5e3d37701814232a9c5a50b496bf026078db4141bfa8